Skip to main content
SpringerLink
Log in

Neuroendocrine and Immune Aspects of Fibromyalgia

  • Review Article
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

Fibromyalgia is a form of non-articular rheumatism characterised by long term (>3 months) and widespread musculoskeletal aching, stiffness and pressure hyperalgesia at characteristic soft tissue sites, called soft tissue tender points. The biophysiology of fibromyalgia, however, has remained elusive and the treatment remains mainly empirical. This article reviews the neuroendocrine-immune pathophysiology of fibromyalgia. There is no major evidence that fibromyalgia is accompanied by activation of the inflammatory response system, by immune activation or by an inflammatory process. There is some evidence that fibromyalgia is accompanied by some signs of immunosuppression, suggesting that immunomodifying drugs could have potential in the treatment of fibromyalgia. Recent trials with cytokines, such as interferon-α, have been undertaken in patients with fibromyalgia. Immunotherapy with these agents, however, may induce symptoms reminiscent of fibromyalgia and depression in a considerable number of patients. Lowered serum activity of prolyl endopeptidase (PEP), a cytosolic endopeptidase that cleaves peptide bonds on the carboxyl side of proline in proteins of relatively small molecular mass, may play a role in the biophysiology of fibromyalgia through diminished inactivation of algesic and depression-related peptides, e.g. substance P. Trials with PEP agonists could be worthwhile in fibromyalgia. The muscle energy depletion hypothesis of fibromyalgia is supported by findings that this condition is accompanied by lowered plasma levels of branched chain amino acids (BCAAs), i.e. valine, leucine and isoleucine. Since there is evidence that BCAA supplementation decreases muscle catabolism and has ergogenic values, a supplemental trial with BCAAs in fibromyalgia appears to be justified.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Similar content being viewed by others

References

  1. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33: 160–72

    Article  CAS  PubMed  Google Scholar 

  2. Schochat T, Croft P, Raspe H. The epidemiology of fibromyalgia. Workshop of the Standing Committee on Epidemiology European League Against Rheumatism. Br J Rheumatol 1994; 33: 783–6

    Article  CAS  PubMed  Google Scholar 

  3. Hudson JI, Pope HG. Fibromyalgia and psychopathology: is fibromyalgia a form of affective spectrum disorder? J Rheumatol 1989; 19: 15–22

    CAS  Google Scholar 

  4. Felson DT, Goldenberg DL. The natural history of fibromyalgia. Arthritis Rheum 1986; 29: 1522–6

    Article  CAS  PubMed  Google Scholar 

  5. Stromorken H, Brosstad F. Fibromyalgia: family clustering and sensory urgency with early onset indicate genetic predisposition and thus a true disease. Scan J Rheumatol 1992; 21: 207

    Article  Google Scholar 

  6. Weinberger LM. Traumatic fibromyositis: a critical review of an enigmatic concept. West J Med 1977; 127: 99–103

    CAS  PubMed  Google Scholar 

  7. Goldenberg DL. Fibromyalgia and other chronic fatigue syndromes: is there evidence for chronic viral disease? Semin Arthritis Rheum 1988; 18: 111–20

    Article  CAS  PubMed  Google Scholar 

  8. Maes M. Major depression and activation of the inflammatory response system. Adv Exp Med Biol 1999; 461: 25–46

    Article  CAS  PubMed  Google Scholar 

  9. Wallace DJ, Bowman RL, Wormsley SB, et al. Cytokines and immune regulation in patients with fibrositis. Arthritis Rheum 1989; 32: 1334–5

    Article  CAS  PubMed  Google Scholar 

  10. Peter JB, Wallace DJ. Abnormal immune regulation in fibromyalgia. Arthritis Rheum 1988; 31: S24

    Google Scholar 

  11. Russell IJ, Vipraio GA, Tovar Z, et al. Abnormal T cell sub-populations in fibrositis syndrome. Arthritis Rheum 1988; 31: S99

    Article  Google Scholar 

  12. Russell IJ, Vipraio GA, Tovar Z, et al. Abnormal natural killer cell activity in fibrositis syndrome is responsive in vitro to IL-2. Arthritis Rheum 1988; 31: S24

    Google Scholar 

  13. Denicoff KD, Rubinow DR, Papa MZ. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 1987; 107: 293–300

    CAS  PubMed  Google Scholar 

  14. Rosenberg SA, Lotze MT, Muul LM. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 316: 889–97

    Article  CAS  PubMed  Google Scholar 

  15. Russell IJ, Vipraio GA, Michalek JE, et al. Lymphocyte markers and natural killer cell activity in fibromyalgia syndrome: effects of low-dose, sublingual use of human interferonalpha. J Interferon Cytokine Res 1999; 19: 969–78

    Article  CAS  PubMed  Google Scholar 

  16. Hernanz W, Valenzuela A, Quijada J, et al. Lymphocyte sub-populations in patients with primary fibromyalgia. J Rheumatol 1994; 21: 2122–4

    CAS  PubMed  Google Scholar 

  17. Cebrian M, Sanchez-Mateos P, Redondo JM, et al. CD69: a GP33/27 kDa activation inducer molecule (AIM) recognized by a group of mAB of the Workshop activation panel. Induction of T-cell proliferation through the AIM activation antigen. In: Kanapp W, Dorken B, Gilks WR, editors. Leukocyte typing-4: white cell differentiation antigens. Venna: Oxford University Press, 1989: 441–4

    Google Scholar 

  18. Schwarting R, Niedobitek G, Stein H. Activation antigens. A4 Cluster report: CD69. In: Kanapp W, Dorken B, Gilks WR, editors. Leukocyte typing-4: white cell differentiation antigens. Venna: Oxford University Press, 1989: 428–32

    Google Scholar 

  19. Murakawa Y, Sakane T. Deficient phytohemagglutinin-induced interleukin-2 activity in patients with inactive systemic lupus erythematosus is correctable by the addition of phorbol myristate acetate. Arthritis Rheum 1988; 31: 826–33

    Article  CAS  PubMed  Google Scholar 

  20. Hader N, Rimon D, Kinarty A, et al. Altered interleukin-2 secretion in patients with primary fibromyalgia syndrome. Arthritis Rheum 1991; 34: 866–72

    Article  CAS  PubMed  Google Scholar 

  21. Allen AD. Is RA27/3 rubella immunization a cause of chronic fatigue? Med Hypotheses 1988; 27: 217–20

    Article  CAS  PubMed  Google Scholar 

  22. Buchwald D, Goldenberg DL, Sullivan JL, et al. The chronic, active Epstein-Barr virus infection syndrome and primary fibromyalgia. Arthritis Rheum 1987; 30: 1132–6

    Article  CAS  PubMed  Google Scholar 

  23. Caro XJ. Is there an immunologic component to the fibrositis syndrome? Rheum Dis Clin North Am 1989; 15: 169–86

    CAS  PubMed  Google Scholar 

  24. Bridges AJ. Fibromyalgia, antinuclear antibodies and clinical features of connective tissue disease [letter]. Clin Exp Rheum 1993; 11:696–7

    CAS  Google Scholar 

  25. Hench PK, Mitler MM. Fibromyalgia 2: management guidelines and research findings. Postgrad Med 1986; 80: 57–69

    CAS  PubMed  Google Scholar 

  26. Smart PA, Waylonis GW, Hackshaw KV. Immunologic profile of patients with fibromyalgia. Am J Phys Med Rehabil 1997; 76: 231–4

    Article  CAS  PubMed  Google Scholar 

  27. Yunus MB, Hussey FX, Aldag JC. Antinuclear antibodies and connective tissue disease features in fibromyalgia syndrome: controlled study. J Rheumatol 1993; 20: 1557–60

    CAS  PubMed  Google Scholar 

  28. Klein R, Bansch M, Berg PA. Clinical relevance of antibodies against serotonin and gangliosides in patients with primary fibromyalgia syndrome. Psychoneuroendocrinol 1992; 17: 593–8

    Article  CAS  Google Scholar 

  29. Burda CD. Immunoglobulin-G deposits at the dermal-epidermal junction in secondary (traumatic) fibromyalgia syndrome. Clin Exp Rheum 1984; 2: 195

    CAS  Google Scholar 

  30. Caro XJ. Immunofluorescent studies of skin in primary fibrositis syndrome. Am J Med 1986; 81: 43–9

    Article  CAS  PubMed  Google Scholar 

  31. Cunha FQ, Poole S, Lorenzetti BB, et al. The pivotal role of tumour necrosis factor alpha in the development of inflammatory hyperalgesia. Br J Pharmacol 1992; 107: 660–4

    Article  CAS  PubMed  Google Scholar 

  32. DeLeo JA, Colburn RW, Nichols M, et al. Interleukin-6-mediated hyperalgesia/allodynia and increased spinal IL-6 expression in a rat mononeuropathy model. J Interferon Cytokine Res 1996; 16: 695–700

    Article  Google Scholar 

  33. Oka T, Aou S, Hori T. Intracerebroventricular injection of interleukin-1 beta enhances nociceptive neuronal responses of the trigeminal nucleus caudalis in rats. Brain Res 1994; 656: 236–44

    Article  CAS  PubMed  Google Scholar 

  34. Maes M, Libbrecht I, Van Hunsel F, et al. The immune-inflammatory pathophysiology of fibromyalgia: increased serum soluble gp 130, the common signal transducer protein of various neurotrophic cytokines. Psychoneuroendocrinol 1999; 24: 371–83

    Article  CAS  Google Scholar 

  35. Maes M. The immune pathophysiology of major depression. In: Honig A, Van Praag HM, editors. Depression, neurobiological, pathophysiological and therapeutic advances. Chichester: Wiley, 1997: 197–215

    Google Scholar 

  36. Bonaccorso S, Lin A, Verkerk R, et al. Immune markers in fibromyalgia: comparison with major depressed patients and normal volunteers. J Affect Disord 1998; 48: 75–82

    Article  CAS  PubMed  Google Scholar 

  37. Xu XJ, Hao JX, Andell-Jonsson S, et al. Nociceptive responses in interleukin-6-deficient mice to peripheral inflammation and peripheral nerve section. Cytokine 1997; 9: 1028–33

    Article  CAS  PubMed  Google Scholar 

  38. Czlonkowski A, Stein C, Herz A. Peripheral mechanisms of opioid antinociception in inflammation: involvement of cytokines. Eur J Pharmacol 1993; 242: 229–35

    Article  CAS  PubMed  Google Scholar 

  39. Wallace DJ, Margolin K, Waller P. Fibromyalgia and interleukin-2 therapy for malignancy. Ann Intern Med 1988;108: 909

    CAS  PubMed  Google Scholar 

  40. Maes M, Capuron L, Ravaud A, et al. Lowered serum dipeptidyl peptidase IV activity is associated with depressive symptoms and cytokine production in cancer patients receiving interleukin-2-based immunotherapy. Neuropsychopharmacol 2001; 24: 130–40

    Article  CAS  Google Scholar 

  41. Crofford LJ, Pillemer SR, Kalogeras KT, et al. Hypothalamicpituitary-adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum 1994; 37: 1583–92

    Article  CAS  PubMed  Google Scholar 

  42. Maes M, Lin A, Bonaccorso S, et al. Increased baseline hypothalamic-pituitary-adrenal axis activity in patients with post-traumatic stress disorder and major depression, but not in patients with fibromyalgia. Acta Psychiatr Scand 1998; 98: 328–35

    Article  CAS  PubMed  Google Scholar 

  43. Chrousos GP, Gold PW. The concept of stress and stress system disorders: overview of physical and behavioral homeostasis. JAMA 1992; 276: 1244–52

    Article  Google Scholar 

  44. Neeck G, Riedel W. Neuromediator and hormonal perturbations in fibromyalgia syndrome: results of chronic stress? Baillières Clin Rheumatol 1994; 8: 763–75

    Article  CAS  PubMed  Google Scholar 

  45. Clauw DJ, Chroussos GP. Chronic pain and fatigue syndromes: overlapping clinical and neuroendocrine features and potential pathogenic mechanisms. Neuroimmunomodulation 1997; 4: 134–53

    CAS  PubMed  Google Scholar 

  46. Torpy DJ, Papanicolaou DA, Lotsikas AJ, et al. Responses of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis to interleukin-6. Arthritis Rheum 2000; 43: 872–80

    Article  CAS  PubMed  Google Scholar 

  47. Vaeroy H, Helle R, Forre O, et al. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain 1988; 32: 21–6

    Article  CAS  PubMed  Google Scholar 

  48. Schwarz MJ, Spath M, Muller-Bardorff H, et al. Relationship of substance P, 5-hydroxyindole acetic acid and tryptophan in serum of fibromyalgia patients. Neurosci Lett 1999; 259: 196–8

    Article  CAS  PubMed  Google Scholar 

  49. Maes M, Libbrecht I, Van Hunsel F, et al. Lower serum activity of prolyl endopeptidase in fibromyalgia is related to severity of depressive symptoms and pressure hyperalgesia. Psychol Med 1998; 28: 957–65

    Article  CAS  PubMed  Google Scholar 

  50. Pernow B. Substance P. Pharmacol Rev 1983; 35: 85–141

    CAS  PubMed  Google Scholar 

  51. Saria A. The role of substance P and other neuropeptides in transmission of pain. Acta Neurochirurgica 1987; 38 Suppl.: 33–5

    Article  CAS  PubMed  Google Scholar 

  52. Sandberg BEB, Iversen LL. Substance P. J Med Chem 1982; 25: 1009–15

    Article  CAS  PubMed  Google Scholar 

  53. Kato T, Okada M, Nagatsu T. Distribution of post-proline cleaving enzyme in human brain and the peripheral tissues. Mol Cell Biochem 1980; 32: 117–21

    Article  CAS  PubMed  Google Scholar 

  54. Moriyama A, Nakanishi M, Sasaki M. Porcine muscle endopeptidase and its endogenous substrates. J Biochem 1988; 104: 112–7

    CAS  PubMed  Google Scholar 

  55. Yunus MB, Dailey JW, Aldag JC, et al. Plasma tryptophan and other amino acids in primary fibromyalgia: a controlled study. J Rheumatol 1992; 19:90–4

    CAS  PubMed  Google Scholar 

  56. Russell IJ, Michalek JE, Vipraio GA, et al. Serum amino acids in fibrositis/fibromyalgia syndrome. J Rheumatol 1989; 19 Suppl.: 158–63

    CAS  Google Scholar 

  57. Moldofsky H, Warsh JJ. Plasma tryptophan and musculoskeletal pain in non-articular rheumatism (’fibrositis syndrome’). Pain 1978; 5: 65–71

    Article  CAS  PubMed  Google Scholar 

  58. Russell IJ, Michalek JE, Vipraio GA, et al. Platelet 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome. J Rheumatol 1992; 19: 104–9

    CAS  PubMed  Google Scholar 

  59. Maes M, Meltzer HYM. The serotonin hypothesis of major depression. In: Bloom F, Kupher D. editors. Psychopharmacology: the fourth generation of progress. Nw York: Raven Press, 1995: 933–44

    Google Scholar 

  60. Maes M, Verkerk R, Delmeire L, et al. Serotonergic markers and lowered plasma branched-chain-amino acid concentrations in fibromyalgia. Psychiatry Res 2000; 97: 11–20

    Article  CAS  PubMed  Google Scholar 

  61. Bengtsson A, Henriksson KG, Larsson J. Reduced high-energy phosphate levels in the painful muscles of patients with primary fibromyalgia. Arthritis Rheum 1986; 29: 817–21

    Article  CAS  PubMed  Google Scholar 

  62. Park JH, Phothimat P, Oates CT, et al. Use of P-31 magnetic resonance spectroscopy to detect metabolic abnormalities in muscles of patients with fibromyalgia. Arthritis Rheum 1998; 41:406–13

    Article  CAS  PubMed  Google Scholar 

  63. Vestergaard-Poulsen P, Thomsen C, Norregaard J, et al. 3 1P NMR spectroscopy and electromyography during exercise and recovery in patients with fibromyalgia. J Rheumatol 1995; 22: 1544–51

    CAS  PubMed  Google Scholar 

  64. Samanin R, Valzelli L. Serotoninergic neurotransmission and morphine activity. Arch Int Pharmacodyn Ther 1972; 196 Suppl.: 138–41

    PubMed  Google Scholar 

  65. Harvey JA, Lintz CE. Lesion in the medial forebrain bundle: delayed effects on sensitivity to electric shock. Science 1965; 148: 250–2

    Article  CAS  PubMed  Google Scholar 

  66. Tenen SS. The effects of p-chlorophenylalanine, a serotonin depletor, on avoidance, acquisition, pain sensitivity and related behavior in the rat. Psychopharmacologia 1967; 10: 204–19

    Article  CAS  PubMed  Google Scholar 

  67. Lentz MJ, Landis CA, Rothermel J, et al. Effects of selective slow wave sleep disruption on musculoskeletal pain and fatigue in middle aged women. J Rheumatol 1999; 26: 1586–92

    CAS  PubMed  Google Scholar 

  68. Sorensen J, Bengtsson A, Backman E, et al. Pain analysis in patients with fibromyalgia. Effects of intravenous morphine, lidocaine and ketamine. Scand J Rheumatol 1995; 24: 360–5

    Article  CAS  PubMed  Google Scholar 

  69. Sorensen J, Bengtsson A, Ahlner J, et al. Fibromyalgia: are there different mechanisms in the processing of pain? A double-blind cross-over comparison of analgesic drugs. J Rheumatol 1997; 24: 1615–21

    CAS  PubMed  Google Scholar 

  70. Godfrey RG. A guide to the understanding and use of tricyclic antidepressants in the overall management of fibromyalgia and other chronic pain syndromes. Arch Int Med 1996; 156: 1047–52

    Article  CAS  Google Scholar 

  71. Goldenberg DL, Felson DT, Dinerman H. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum 1986; 29: 1371–7

    Article  CAS  PubMed  Google Scholar 

  72. Simms RW. Controlled trials of therapy in fibromyalgia syndrome. Baillières Clin Rheumatol 1994; 8: 917–34

    Article  CAS  PubMed  Google Scholar 

  73. Moldofsky H, Scarisbrick P. Induction of neurasthenic musculoskeletal pain syndrome by selective sleep stage deprivation. Psychosom Med 1975; 38: 35–44

    Google Scholar 

  74. Frank RG, Kashani JH, Parker JC. Antidepressant analgesia in rheumatoid arthritis. J Rheumatol 1988; 15: 1632–8

    CAS  PubMed  Google Scholar 

  75. Maes M, Song C, Lin A, et al. Anti-inflammatory effects of antidepressants: increased production of interleukin-10 and suppressed production of interferon-gamma. Neuropsychopharmacol 1999; 20: 370–9

    Article  CAS  Google Scholar 

  76. Kubera M, Lin AH, Kenis G, et al. Anti-inflammatory effects of antidepressants through suppression of the interferongamma/interleukin-10 production ratio. J Clin Psychopharmacol 2001; 21: 199–206

    Article  CAS  PubMed  Google Scholar 

  77. Arnold LM, Keck PE, Welge JA. Antidepressant treatment of fibromyalgia: a meta-analysis and review. Psychosom 2000; 41: 104–13

    Article  CAS  Google Scholar 

  78. Carette S, McCain GA, Bell DA. Evaluation of amitriptyline in primary fibrositis: a double-blind, placebo-controlled study. Arthritis Rheum 1986; 29: 655–9

    Article  CAS  PubMed  Google Scholar 

  79. Caruso I, Puttini PC, Boccassini L. Double-blind study of dothiepin versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res 1987; 15: 154–9

    CAS  PubMed  Google Scholar 

  80. Bennett RM, Gatter RA, Campbell SM, et al. A comparison of cyclobenzaprine and placebo in the management of fibrositis. A double-blind controlled study. Arthritis Rheum 1988; 31: 1535–42

    Article  CAS  PubMed  Google Scholar 

  81. Quimby LG, Gratwick GM, Whitney CD, et al. Arandomized trial of cyclobenzaprine for the treatment of fibromyalgia. J Rheumatol 1989; 19 Suppl.: 140–3

    CAS  Google Scholar 

  82. Carette S, Bell MJ, Reynolds WJ. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: a randomized, double-blind clinical trial. Arthritis Rheum 1994; 37: 32–40

    Article  CAS  PubMed  Google Scholar 

  83. Carette S, Oakson G, Guimont C. Sleep electroencephalography and the clinical response to amitriptyline in patients with fibromyalgia. Arthritis Rheum 1995; 38: 1211–7

    Article  CAS  PubMed  Google Scholar 

  84. Reynolds WJ, Moldofsky H, Saskin P. The effects of cyclobenzaprine on sleep physiology and symptoms in patients with fibromyalgia. J Rheumatol 1991; 18: 452–4

    CAS  PubMed  Google Scholar 

  85. Bibolotti E, Borghi C, Pasculli E. The mangement of fibrositis: a double-blind comparison of maprotiline, chlorimipramine, and placebo. J Clin Trials 1986; 23: 269–80

    Google Scholar 

  86. Goldenberg DL, Mayskiy M, Mossey C. Arandomized double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 1996; 39: 1852–9

    Article  CAS  PubMed  Google Scholar 

  87. Ekselius L, Von Knorrin L, Eberhard G. A double-blind multi-center trial comparing sertraline and citalopram in patients with major depression. Int Clin Psychopharmacol 1997; 12: 323–31

    Article  CAS  PubMed  Google Scholar 

  88. Yunus MB, Masi AT, Aldag JC. Short-term effects of ibuprofen in primary fibromyalgia syndrome: a double-blind, placebo controlled trial. J Rheumatol 1989; 16: 527–32

    CAS  PubMed  Google Scholar 

  89. Clark S, Tindall E, Bennett RM. A double-blind cross-over trial of prednisone vs placebo in the treatment of fibrositis. J Rheumatol 1985; 12: 980–3

    CAS  PubMed  Google Scholar 

  90. Biasi G, Manca S, Manganelli S, et al. Tramadol in the fibromyalgia syndrome: a controlled clinical trial versus placebo. Int Clin Pharmacol Res 1998; 18: 13–9

    CAS  Google Scholar 

  91. Russell IJ, Michalek JE, Kang YK, et al. Reduction of morning stiffness and improvement in physical function in fibromyalgia syndrome patients treated sublingually with low doses of human interferon-alpha. J Interferon Cytokine Res 1999; 19: 961–8

    Article  CAS  PubMed  Google Scholar 

  92. Bonaccorso S, Marino V, Puzella A, et al. The increased depressive ratings in hepatitis-C patients receiving interferon-alpha (IFNα)-based immunotherapy are related to IFNα-induced changes in the serotonergic system. J Clin Psychopharmacol. In press

Download references

Author information

Authors and Affiliations

  1. Clinical Research Centre for Mental Health (CRC-MH), Antwerp, Belgium

    Dirk van West &  Michael Maes

  2. Department of Psychiatry and Neuropsychology, University Hospital of Maastricht, Postbus 5800, 6202, AZ Maastricht, The Netherlands

    Michael Maes

  3. Department of Psychiatry, Vanderbilt University, Nashville, Tennessee, USA

    Michael Maes

Authors
  1. Dirk van West
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Maes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Maes.

Rights and permissions

Reprints and permissions

About this article

Cite this article

van West, D., Maes, M. Neuroendocrine and Immune Aspects of Fibromyalgia. BioDrugs 15, 521–531 (2001). https://doi.org/10.2165/00063030-200115080-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-200115080-00004

Keywords

Search

Navigation